Lv1
56 积分 2026-05-11 加入
Lipid-lowering therapy with inclisiran in the real-world setting: Initial data from a national health care service
6天前
已完结
Transformer-based models for predicting cardiovascular risk in Chinese adults: development and validation
17天前
已完结
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
25天前
已完结
The Impact of Inclisiran on Lipid Profiles in Adults with Hyperlipidemia: A Meta-Analysis and Meta-Regression of Randomized Controlled Trials
1个月前
已完结
Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials
1个月前
已完结
Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial
1个月前
已完结
What Inclisiran Monotherapy Teaches Us About LDL-C Regulation and CV Prevention
1个月前
已完结
Inclisiran—will it fulfill its promise?
1个月前
已完结
Inclisiran—will it fulfill its promise?
1个月前
已关闭
Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials
1个月前
已完结
皖公网安备34019202002308
